Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 26 August 1983:
Vol. 221. no. 4613, pp. 865 - 867
DOI: 10.1126/science.6879183
Prev | Table of Contents | Next

Articles

Science, Vol 221, Issue 4613, 865-867
Copyright © 1983 by American Association for the Advancement of Science

articles

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells

Z Steplewski, MD Lubeck, and H Koprowski

Macrophages isolated from tumor-bearing patients as well as cultured human monocytes express Fc receptors that cross-react strongly with murine immunoglobulins of the G2a but only slightly or not at all with the G1, G2b, or G3 subclasses. Such macrophages in the presence of murine immunoglobulin G2a monoclonal antibodies to tumors mediated the killing of tumor cells in vitro. These data suggest that monoclonal antibodies of the G2a subclass may be useful in the immunotherapy of human cancer.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer.
A. L.A. Fields, A. Keller, L. Schwartzberg, S. Bernard, C. Kardinal, A. Cohen, J. Schulz, P. Eisenberg, J. Forster, and P. Wissel (2009)
J. Clin. Oncol. 27, 1941-1947
   Abstract »    Full Text »    PDF »
Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc{gamma}RI and Fc{gamma}RIV.
M. A. Otten, G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. J. Beelen, J. G. J. van de Winkel, and M. van Egmond (2008)
J. Immunol. 181, 6829-6836
   Abstract »    Full Text »    PDF »
Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy.
L. Binyamin, R. K. Alpaugh, T. L. Hughes, C. T. Lutz, K. S. Campbell, and L. M. Weiner (2008)
J. Immunol. 180, 6392-6401
   Abstract »    Full Text »    PDF »
Cathepsin E Prevents Tumor Growth and Metastasis by Catalyzing the Proteolytic Release of Soluble TRAIL from Tumor Cell Surface.
T. Kawakubo, K. Okamoto, J.-i. Iwata, M. Shin, Y. Okamoto, A. Yasukochi, K. I. Nakayama, T. Kadowaki, T. Tsukuba, and K. Yamamoto (2007)
Cancer Res. 67, 10869-10878
   Abstract »    Full Text »    PDF »
Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen.
Y. Tang, J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner (2007)
J. Immunol. 179, 2815-2823
   Abstract »    Full Text »    PDF »
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
R. Brodzik, M. Glogowska, K. Bandurska, M. Okulicz, D. Deka, K. Ko, J. van der Linden, J. H. W. Leusen, N. Pogrebnyak, M. Golovkin, et al. (2006)
PNAS 103, 8804-8809
   Abstract »    Full Text »    PDF »
Antibody Conjugates and Therapeutic Strategies.
P. A. McCarron, S. A. Olwill, W. M.Y. Marouf, R. J. Buick, B. Walker, and C. J. Scott (2005)
Mol. Interv. 5, 368-380
   Abstract »    Full Text »    PDF »
The Evolution of Antibodies into Versatile Tumor-Targeting Agents.
M. Z. Lin, M. A. Teitell, and G. J. Schiller (2005)
Clin. Cancer Res. 11, 129-138
   Abstract »    Full Text »    PDF »
Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format.
L. S. Shahied, Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner (2004)
J. Biol. Chem. 279, 53907-53914
   Abstract »    Full Text »    PDF »
Selection and characterization of HER2/neu-binding affibody ligands.
M. Wikman, A.-C. Steffen, E. Gunneriusson, V. Tolmachev, G.P. Adams, J. Carlsson, and S. Stahl (2004)
Protein Eng. Des. Sel. 17, 455-462
   Abstract »    Full Text »    PDF »
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor-related Cytokine, TRAIL.
T. S. Griffith, S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanger (1999)
J. Exp. Med. 189, 1343-1354
   Abstract »    Full Text »    PDF »
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.
J. H. Sampson, L. E. Crotty, S. Lee, G. E. Archer, D. M. Ashley, C. J. Wikstrand, L. P. Hale, C. Small, G. Dranoff, A. H. Friedman, et al. (2000)
PNAS 97, 7503-7508
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)